Angiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeys.
The enhanced production of monocytes expressing pro-inflammatory markers such as the integrin CD11b in patients with hypercholesterolemia may promote vascular inflammation and exacerbate atherogenesis. The objective of the present study was to determine whether hypercholesterolemia stimulates the production of CD11b(+) monocytes in bone marrow, and whether the renin-angiotensin system participates in this process and thus provides a target for therapeutic intervention. The dietary induction of hypercholesterolemia in adult male cynomolgus monkeys was accompanied by increased bone marrow cellularity and elevated peripheral blood and bone marrow monocyte CD11b expression. Isolated bone marrow CD34(+) hematopoietic stem cells (HSCs) evaluated by in vitro functional assays exhibited enhanced myeloproliferative capacity and differentiation into CD11b(+) monocytes. Treatment of hypercholesterolemic monkeys with the angiotensin II AT(1) receptor blocker losartan for 15 weeks reduced bone marrow cellularity, suppressed peripheral blood and bone marrow monocyte CD11b expression, and normalized CD34(+) cell function assays. All variables returned to pretreatment levels 6 weeks after discontinuation of losartan treatment. Hypercholesterolemia was associated with increased CD34(+) cell AT(1) receptor expression and an exaggerated in vitro myeloproliferative response to angiotensin II stimulation that positively correlated to plasma LDL concentrations. In vitro exposure to native low-density lipoproteins (LDL) also increased CD34(+) cell AT(1) receptor expression and the myeloproliferative response to angiotensin II stimulation in a dose-dependent and receptor-mediated manner. Our data provide support for a positive regulatory role of plasma LDL on AT(1) receptor-mediated HSC differentiation and the production of pro-atherogenic monocytes. LDL-regulated HSC function may explain in part hypercholesterolemia-induced inflammation as well as the anti-inflammatory and anti-atherosclerotic effects of AT(1) receptor blockers.
Strawn
William B
WB
Hypertension and Vascular Research Center, Wake Forest University Health Sciences, Winston-Salem, NC 27157, United States. bstrawn@wfubmc.edu
Ferrario
Carlos M
CM
D000804:Angiotensin II / Q000097:blood; D000818:Animals; D018952:Antigens, CD34 / Q000032:analysis; D001854:Bone Marrow Cells / Q000378:metabolism*; D039481:CD11b Antigen / Q000096:biosynthesis*; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D006937:Hypercholesterolemia / Q000378:metabolism*; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D019808:Losartan / Q000627:therapeutic use; D008252:Macaca fascicularis; D008297:Male; D044140:Receptor, Angiotensin, Type 1 / Q000187:drug effects*; D012084:Renin-Angiotensin System / Q000502:physiology
D018952:Antigens, CD34; D039481:CD11b Antigen; D002791:Cholesterol, Dietary; D044140:Receptor, Angiotensin, Type 1; D000804:Angiotensin II; D002784:Cholesterol; D019808:Losartan
Circulation. 1999 Nov 23;100(21):2131-4
10571970
Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):380-6
17158350
Circulation. 2000 Apr 4;101(13):1586-93
10747353
Cytometry. 2000 May 1;40(1):26-31
10754514
Stem Cells. 2000;18(4):287-94
10924095
Ann Med. 2000 Sep;32(6):386-9
11028685
Diabetes Obes Metab. 2000 Aug;2(4):223-8
11225655
J Am Coll Cardiol. 2001 Nov 15;38(6):1662-7
11704378
Clin Pharmacol Ther. 2002 Jan;71(1):89-98
11823761
J Hum Hypertens. 2002 May;16 Suppl 2:S7-12
11967727
Stem Cells. 2002;20(3):269-71
12004086
J Clin Invest. 2002 Dec;110(12):1859-68
12488436
Diabetes Care. 2003 May;26(5):1540-4
12716819
J Lipid Res. 2003 Jul;44(7):1332-40
12730301
Am J Primatol. 2003 Sep;61(1):3-12
12966515
Blood. 2004 Feb 1;103(3):878-85
14525791
Br J Haematol. 2004 Jul;126(1):120-6
15198742
J Cell Physiol. 1979 May;99(2):233-8
222784
J Lipid Res. 1985 Dec;26(12):1476-80
4086949
Am J Pathol. 1989 Aug;135(2):369-77
2675618
Arteriosclerosis. 1989 Nov-Dec;9(6):848-55
2590064
Blood. 1990 Dec 15;76(12):2483-92
1702327
Arterioscler Thromb. 1991 Jul-Aug;11(4):985-94
2065049
Circulation. 1997 Jan 21;95(2):473-8
9008466
J Am Coll Cardiol. 1997 Nov 1;30(5):1212-7
9350917
Tissue Antigens. 1998 Feb;51(2):141-55
9510370
J Immunol. 2006 May 1;176(9):5577-86
16622027
Regul Pept. 2006 May 15;134(2-3):69-74
16530863
Adv Cardiol. 2007;44:315-30
17075218
J Hypertens. 1999 Dec;17(12 Pt 2):1933-9
10703892